Shanthi Viswanathan - Neurology

Author Information

Shanthi Viswanathan is a prominent neurologist affiliated with the Department of Neurology at Kuala Lumpur Hospital, located in Jalan Pahang, Kuala Lumpur, Malaysia. Her work primarily revolves around neurological diseases, and she has a significant presence in the field of neurology within the Southeast Asian region. Her affiliation with a major hospital indicates her active involvement in both clinical practice and research.

Research Contributions

Shanthi Viswanathan has made substantial contributions to the field of neurology, focusing on therapeutic plasma exchange and neuromyelitis optica spectrum disorder (NMOSD). Her research includes examining the impacts of treatments such as eculizumab and providing consensus recommendations for managing neurological diseases in Southeast Asia. She has also delved into the genetic aspects of Parkinson’s disease and explored the ethical use of off-label therapies for multiple sclerosis. Her work is crucial in addressing the challenges of neurological diseases in both clinical and ethical dimensions.

Aliases

Shanthi Viswanathan is known by several aliases in academic publications, including "S Viswanathan," "S. Viswanathan," and "Shanthi Viswanathan." These variations are commonly used in her published works.

Publication and Citation Metrics

Metric	Value
Citation Count	830
H-Index	12
Paper Count	77

Publications:

Consensus recommendation on the use of therapeutic plasma exchange for adult neurological diseases in Southeast Asia from the Southeast Asia therapeutic plasma exchange consortium

DOI: 10.1177/11795735211057314

Year: 2021

Impact of Covid‐19 on the therapeutic plasma exchange service within the South East Asian region: Consensus recommendations and global perspectives

DOI: 10.1002/jca.21937

Year: 2021

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.

DOI: 10.1016/j.msard.2021.102849

Year: 2021

Ethical use of off-label disease-modifying therapies for multiple sclerosis

DOI: 10.1177/13524585211030207

Year: 2021

A retrospective analysis of emerging rabies: a neglected tropical disease in Sarawak, Malaysia.

DOI: 10.4997/JRCPE.2021.207

Year: 2021

Association study of MCCC1/LAMP3 and DGKQ variants with Parkinson’s disease in patients of Malay ancestry

DOI: 10.1007/s10072-021-05056-x

Year: 2021

Toluene-induced leukodystrophy from glue sniffing

DOI: 10.1136/practneurol-2021-002942

Year: 2021

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.

DOI: 10.1016/j.msard.2020.102641

Year: 2020

Sequential intermittent therapeutic plasma exchange: A possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder

DOI: 10.1111/1744-9987.13595

Year: 2020

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788)

DOI:

Year: 2020

How are Potential Risks and Complications Addressed?

How Does Neurostimulation Work?

How is Peripheral Neuropathy Diagnosed?

How Do CT Scans Work?

How is Myelin Studied in Neurology?

How are migraines managed?

How is PPMS Different from Other Types of MS?

What is the Prognosis for Patients?

What Causes Multiple Sclerosis?

What is Neuromyelitis Optica (NMO)?

Partnered Content Networks

Relevant Topics